Pacira BioSciences (PCRX) CMO logs 6,168-share tax withholding on RSU vesting

(Moderate)

(Negative)

Form Type

Rhea-AI Filing Summary

Pacira BioSciences Chief Medical Officer reports tax-share withholding. Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc., reported a Form 4 transaction involving company common stock. On 01/30/2026, 6,168 shares of common stock were withheld by Pacira to cover tax obligations when a restricted stock unit award vested at a price of $20.54 per share.

After this withholding, Slonin directly beneficially owned 172,355.175 shares of Pacira common stock. The transaction reflects tax-related share withholding rather than an open-market sale.

Insider Trade Summary

Net Seller: 6,168 shares

Net Sell 1 txn

Insider SLONIN JONATHAN

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	6,168	$20.54	$127K

Holdings After Transaction: Common Stock — 172,355.175 shares (Direct)

Footnotes (1)

F1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

FAQ

What insider transaction did Pacira BioSciences (PCRX) report for Jonathan Slonin?

Pacira BioSciences reported that Chief Medical Officer Jonathan Slonin had 6,168 shares of common stock withheld on 01/30/2026. These shares were retained by the company to satisfy tax withholding obligations tied to the vesting of a restricted stock unit award, not an open-market sale.

How many Pacira (PCRX) shares were withheld for Jonathan Slonin’s taxes?

A total of 6,168 Pacira common shares were withheld for Jonathan Slonin on 01/30/2026. According to the filing, the issuer retained these shares to cover tax withholding obligations arising from the vesting of a restricted stock unit award granted to the Chief Medical Officer.

At what price were Pacira (PCRX) shares withheld in Jonathan Slonin’s Form 4 filing?

The shares withheld for Jonathan Slonin’s tax obligations were valued at $20.54 per Pacira common share. This price is shown in the Form 4 table describing the non-derivative transaction related to the restricted stock unit vesting and associated tax-share withholding.

How many Pacira (PCRX) shares does Jonathan Slonin hold after this transaction?

Following the 6,168-share tax withholding, Jonathan Slonin beneficially owned 172,355.175 Pacira common shares directly. This post-transaction balance is reported in the Form 4 and reflects his remaining direct holdings after the restricted stock unit vesting tax adjustment.

Was Jonathan Slonin’s Pacira (PCRX) Form 4 a market sale or tax withholding?

The Form 4 shows a tax withholding, not a market sale. The filing notes that 6,168 shares were withheld by Pacira to cover tax obligations triggered by the vesting of a restricted stock unit award, meaning shares did not go through an open-market transaction.

What role does Jonathan Slonin hold at Pacira BioSciences (PCRX)?

Jonathan Slonin is identified as an officer of Pacira BioSciences, serving as Chief Medical Officer. The Form 4 confirms his officer status and shows that he files individually as the reporting person for this restricted stock unit vesting-related tax withholding transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/03/2026 - 06:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SLONIN JONATHAN

(Last)

(First)

(Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE

94005

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/30/2026		F		6,168⁽¹⁾	D	$20.54	172,355.175	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR